• Waldenström Macroglobulinemia
  • Melanoma
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Mesothelioma
  • MPN
  • MDS
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer

ASCO: More answers, and questions, on best hormonal therapy for early-stage breast cancer

Article

Debu Tripathy blog image

Debu Tripathy, CURE's editor-in-chief, is in Chicago for the annual meeting of the American Society of Clinical Oncology. He explains an analysis of two early-stage breast cancer studies in premenopausal women. The study revealed that exemestane was better than tamoxifen in patients who had ovarian blockade. After four years there was a reduction in recurrence risk, as well as a slight increase in survival. An analysis that would compare these results to tamoxifen alone is still awaited. "We're not quite ready to change hormonal therapy for all premenopausal women," he says. "But that may end up being the case; we may know more in about six months."

Related Videos
A man with a dark gray button-up shirt with glasses and cropped brown hair.
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE